Altimmune, Inc. (ALT)
2.785
-0.02
(-0.89%)
USD |
NASDAQ |
May 19, 14:35
Altimmune Research and Development Expense (Quarterly) : 16.17M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.51B |
| Madrigal Pharmaceuticals, Inc. | 108.31M |
| Amgen, Inc. | 1.719B |
| Verastem, Inc. | 38.22M |
| Karyopharm Therapeutics, Inc. | 33.78M |